Axsome Insider Executes Option Exercises and Open-Market Sales on 09/16/2025
Rhea-AI Filing Summary
Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, Inc. (AXSM), reported option exercises and open-market sales on 09/16/2025. He exercised two stock option grants: 25,000 shares at $4.95 (issued 03/15/2018) and 15,000 shares at $4.85 (issued 09/13/2018), generating 40,000 underlying shares. All 40,000 shares were subsequently sold in open-market transactions under a pre-approved 10b5-1 plan for weighted average prices of $116.19 and $114.23, resulting in no shares owned following the sales. The exercises were necessary due to the options approaching their 10-year expiration.
Positive
- Transactions were executed under a pre-approved 10b5-1 plan, indicating procedural compliance.
- Option exercises occurred before expiration, avoiding automatic forfeiture and preserving value for the reporting person.
- Open-market sale prices ($112.93–$116.87 range) were substantially above the option strike prices ($4.95 and $4.85), creating significant gain for the reporting person.
Negative
- The reporting person no longer beneficially owns any common shares following the reported sales, reducing insider ownership.
Insights
TL;DR: Insider exercised and sold all option-derived shares under a 10b5-1 plan; transactions are liquidity events, not necessarily a signal on fundamentals.
The filing shows the COO exercised a total of 40,000 options and sold the resulting shares the same day under a pre-established 10b5-1 plan. The exercises were required by option expirations, indicating a timing-driven disposition rather than opportunistic sale only. The proceeds per share ranged from about $114.23 to $116.19, materially above the option strike prices ($4.95 and $4.85), producing substantial spread for the reporting person. For investors, this is routine insider liquidity and option lifecycle activity rather than a disclosed change in company operations or financial outlook.
TL;DR: Transactions followed governance controls: exercises due to expirations and sales under a pre-approved 10b5-1 plan, showing procedural compliance.
The Form 4 indicates compliance with governance mechanisms: the sale activity was executed pursuant to a pre-approved 10b5-1 trading plan and the option exercises were compelled by 10-year expiry dates. The filing is properly signed and discloses sale prices and option details. From a governance perspective, disclosures are complete and timely, and the use of a 10b5-1 plan reduces concerns about opportunistic insider timing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Sale | Common Stock | 5,783 | $116.19 | $672K |
| Exercise | Common Stock | 25,000 | $4.95 | $124K |
| Exercise | Common Stock | 15,000 | $4.85 | $73K |
| Sale | Common Stock | 40,000 | $114.23 | $4.57M |
Footnotes (1)
- Represents the sale of underlying shares of previously exercised stock options. Such transaction was pursuant to a pre-approved 10b5-1 plan. Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. Represents the sale price of all shares in an open market transaction. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $112.93 and $116.87.
